Pfizer–BioNTech COVID-19 vaccine
Comirnaty has been licensed on 23/8/2021. The Pfizer vaccine available in the United States in September and October 2021 has not been licensed in the United States. Officially, the two vaccines are the same; however, the Comirnaty vaccine is not available in the U.S. at the present moment. All in all, that seems a minor issue.
OBFUSCATION
Oddly, the CDC documents prefer not to easily give the exact number of people who received the vaccine in the trials. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html
From other medical reviews, we get the figure of 36,901 people who in the Pfizer and in the Moderna trials received the vaccine.
The FDA however, on page 42 of its Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum, advises us that there were N=37,586 participants in the trials, of which 18,801 took the vaccine and 18,785 got the placebo. They had follow-up of 2 months. Six thousand more were enrolled, but did not receive the minimum observation period of two months. https://www.fda.gov/media/144416/download
Most side effects are mild to moderate in severity and are gone within a few days.[34][3] The most common include mild to moderate pain at the injection site, fatigue, and headaches.[35][36] Reports of serious side effects, such as allergic reactions, are very rare[a] and no long-term complications have been reported.[3][38]
The frequency of non-fatal serious adverse events was low (<0.5%), without meaningful imbalances between study arms. The most common SAEs in the vaccine arm which were numerically higher than in the placebo arm were appendicitis (0.04%), acute myocardial infarction (0.02%), and cerebro-vascular accident (0.02%)... https://www.fda.gov/media/144416/download
A CONFLICT BETWEEN FDA AND CDC DATA
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability/incapacity. The proportions of participants who reported at least 1 serious adverse event were 0.6% in the vaccine group and 0.5% in the placebo group. The most common serious adverse events in the vaccine group which were numerically higher than in the placebo group were appendicitis (7 in vaccine vs 2 in placebo), acute myocardial infarction (3 vs 0), and cerebrovascular accident (3 vs 1). https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html
So they told us. Appendicitis, heart attack, and stroke. The difference between 0.5% and 0.6%, is 1/1000, which would result in 330,000 catastrophic events for American families. Not to mention the much more common trifles, such as non-total loss of hearing and sight, lymphadenopathy, eczema, mental fog, migraine, epilepsy, tinnitus that does not allow you sleep, vertigo that makes work or normal life impossible.
The statistics for young people between 12 and 15 years are different. Only 0.2% of the controls who received water injections ended up in the hospital, one in every 500. The vaccinated, on the other hand, had twice as many hospitalizations, 0.4%.
Appendicitis was the most common SAE in the vaccine arm. There were 12 participants with SAEs of appendicitis; 8 in the BNT162b2 group.
Of the 8 total appendicitis cases in the BNT162b2 group, 6 occurred in the younger (16 to 55 years) age group and 2 occurred in the older (>55 years) age group (one of the cases in the older age group was perforated). One of the 6 participants with appendicitis in the younger age group also had a peritoneal abscess. Cases of appendicitis in the vaccine group were not more frequent than expected in the general population. https://www.fda.gov/media/144416/download
APPENDICITIS RISE IN CASES IS CAREFULLY HIDDEN
In 2010 there were 293,000 appendicitis hospitalisations in the U.S. That would tell us to expect 16 in a group of 19,000 people. That is less than the 8 that were observed in the Pfizer trials.
The problem is that the 18,901 were observed for only two months. Dividing 16 by 6, we conclude that over the course of two months we should have expected 2.5 cases, not 8: the cases were indeed more frequent than expected.
Unsolicited Adverse Events
Reports of lymphadenopathy were imbalanced with 58 more cases in the vaccine group (64) than the placebo group (6); lymphadenopathy is plausibly related to the vaccine. Lymphadenopathy occurred in the arm and neck region and was reported within 2 to 4 days after vaccination. The average duration of lymphadenopathy was approximately 10 days. https://www.fda.gov/media/144416/download
LYMPHADENOPATHY
It appears that lymphadenopathy is the only condition for which Pfizer recognises responsibility. Some particularly zealous medical servants of Pharma will go as far as saying that it's a good sign. The swelling of the lymph nodes, usually is a warning sign of problems; however, after Pfizer, it is a sign of the vaccine working, according to some. Then if lymphadenopathy does not develop, does it means the stuff is not working?
Serious Adverse Events
Serious adverse events were defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent disability/incapacity. The proportions of participants who reported at least 1 serious adverse event were 0.6% in the vaccine group and 0.5% in the placebo group. The most common serious adverse events in the vaccine group which were numerically higher than in the placebo group were appendicitis (7 in vaccine vs 2 in placebo), acute myocardial infarction (3 vs 0), and cerebrovascular accident (3 vs 1). Cardiovascular serious adverse events were balanced between vaccine and placebo groups. Two serious adverse events were considered by U.S. Food and Drug Administration (FDA) as possibly related to vaccine: shoulder injury possibly related to vaccine administration or to the vaccine itself, and lymphadenopathy involving the axilla contralateral to the vaccine injection site. Otherwise, occurrence of severe adverse events involving system organ classes and specific preferred terms were balanced between vaccine and placebo groups. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html#persons-12-15yrs
Now, for the serious stuff.
Well, no need to discuss it, since the smart folks in charge could not think think up a mechanism by which the events, catastrophic events for individuals and for families, could have developed. They actually had no ideas about the toxicity of the spike proteins, and it was a shock when that was revealed. So they ascribed it all--stroke, paralysis, heart attack them all to coincidence and Acts of God.
On March 31, 2021, a surprise: Circulation Research published a study by Lei et al. It reports that "We administered a pseudovirus expressing S protein (Pseu-Spike) to Syrian hamsters... Lung damage was apparent in animals receiving Pseu-Spike ...our data reveals that S protein alone can damage endothelium. https://www.covidr.org/en/97-since-december-the-spike-protein-warnings-were-ignored
Everyone stayed mum. No delay in the vaccination campaign. Even against the advice of the WHO, they pushed to vaccinate kids.
At least three times more frequent were appendicitis, heart attack, and stroke. "None of our problem", they said, and continue to say to this day, in contempt of the evidence and of the explanation from Circulation Research .
THE VICTIMS
One of the participants in the 12-15 age group of 1127 adolescents, Maddie de Garay, appeared in a wheelchair at a press conference of Senator Johnson of Wisconsin, wearing a feeding tube. She is paralyzed. https://rumble.com/vj5xbf-senator-ron-johnson-milwaukee-news-conference.html.
With her mother, she appeared again at a U.S. Senate hearing, when a number of victims and medical experts gave testimony. The event can be seen at https://rumble.com/vokrf7-sen.-johnson-expert-panel-on-federal-vaccine-mandates.html The recording starts at 30' 50".
Here, from the FDA report, is the paragraph that might have referred to Ms. De Garay: One participant experienced an SAE reported as generalized neuralgia, and also reported 3 concurrent non-serious AEs (abdominal pain, abscess, gastritis) and 1 concurrent SAE (constipation) within the same week. The participant was eventually diagnosed with functional abdominal pain. The event was reported as ongoing at the time of the cutoff date.
Another possibility is that Ms. De Garay may have been left out of the report, altogether.
So perhaps they did not cook up the trials, they just obfuscated the results, so that no one could notice the catastrophe they were preparing for us. There is a difference between having abdominal pain and being paralysed.